期刊文献+

HER-2癌基因反义寡脱氧核苷酸对乳腺癌细胞放射敏感性的影响 被引量:1

Effect of HER-2 oncogene antisense oligodeoxynucleotides on radiosensityivity of breast cancer cell line
下载PDF
导出
摘要 目的探讨癌基因HER-2反义寡核苷酸联合放疗对乳腺癌细胞的影响。方法实验分组如下:HER-2反义寡脱氧核苷酸组、HER-2正义寡脱氧核苷酸组、叶酸对照组和空白对照组。用RT-PCR方法、MTT法及平板克隆形成实验检测乳腺癌细胞SK-Br-3受药物处理后,经60Coγ射线照射,HER-2表达水平、细胞存活分数和集落形成率的改变。结果经HER-2反义寡核苷酸-叶酸处理的细胞,对60Coγ射线的放射敏感性增加,细胞的HER-2癌基因表达水平降低,存活分数及集落形成率与正义寡核苷酸、叶酸和空白对照组比较明显降低(P<0.05),而正义寡核苷酸、叶酸与空白对照组相比无明显差异(P>0.05)。结论HER-2反义寡核苷酸抑制癌基因表达的作用增加乳腺癌细胞SK-Br-3对放疗的敏感性。 Objective To explore the effect of HER-2 oncogene antisense oligodeoxynucleotides on radiosensitivity of breast cancer cell line. Methods To set up HER-2 antisense oligodeoxynucleotides (ASODN) experimental group, sense oligodeoxynueleotides (SODN) group, folate acid (FA) group and ^60Co irradiation control group. The expression of HER 2 was detected by means of RT-PCR. Cel lular response to irradiation was evaluated by the colony forming test and MTT assay. Results HER-2 ASODN could suppress the expression of c-erbB2 which significantly increased the radiosensitivity of breast cancer cells (P〈0. 05), while folate acid group and the SODN group did not increase the radiosensilivity of SK-Br-3 cell line. Conclusion HER 2 antisense oligodeoxynucleotides sensitized the breast cancer cell SK Br-3 to ionizing irradiation through decreasing the expression of HER-2.
出处 《贵州医药》 CAS 2006年第12期1059-1062,共4页 Guizhou Medical Journal
基金 贵州省优秀科技教育人才省长专项资金资助项目[编号:黔省专合字(2005)36号]
关键词 HER-2反义寡脱氧核苷酸 叶酸 乳腺癌 放射敏感性 HER-2 antisense oligodeoxynucleotides Folate acid Breast cancer Radiosensitivity
  • 相关文献

参考文献14

  • 1Bundred NJ.Prognostic and predictive factors in breast cancer[J].Cancer Treat Rev,2001,27 (3):137-142.
  • 2Hideko Yamauchi,Vered Stearns,Daniel F Hayes.When is a tumor Marker ready for prime time? A case study of c-erbB 2 as a predictive factor in breast cancer[J].Journal of Clinical Oncology,2001,19(8):2 334-2 356.
  • 3Michele A.Bonham,Stephen Brown,Ann L.Boyd,et al.An assessement of the antisense properties of RNase Hcompetent and steric-blocking oligomers[J].Nucleic Acids Research,1995,23(7):1 197-1 203.
  • 4谢娟,郭坤亮,李少林.叶酸受体介导^(99m)Tc标记c-erbB2癌基因反义寡核苷酸的乳腺癌细胞摄取率[J].贵州医药,2005,29(1):13-15. 被引量:7
  • 5Koukourakis MI,Giatromanolaki A,Galazios G,et al.Molecular analysis of local relapse in high-risk breast cancer patients:canradiotherapy fractionation and time factors make a difference[J]? Br J Cancer,2003,10,88(5):711-717.
  • 6Koukourakis MI.Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC):a new concept in radiotherapy and encouraging results in breast cancer[J].Semin Oncol,2002,29(6 Suppl 19):42-46.
  • 7Pietras RJ,Poen JC,Gallardo D,et al.Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cellsoverexpressing this oncogene[J].Cancer Res.1999,59:1 347-1 355.
  • 8Harari D,Yaraden Y.Molecular mechanisms underlying erbB-2/HER-2 action in breast cancer[J].Oncogene,2000,19(53):6 102-6 114.
  • 9Tsutsui,Shinichi Ohno,Shinji Murakami,et al.Prognostic value of c-erbB2 expression in breast cancer[J].Journal of Surgical Oncology,2002,79(4):216-223.
  • 10Cho HS,Mason K,Ramyar KX,et al.Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab[J].Nature,2003,421 (6 924):756-760.

二级参考文献24

  • 1谢娟,郭坤亮,李少林.叶酸受体介导^(99m)Tc标记c-erbB2癌基因反义寡核苷酸的乳腺癌细胞摄取率[J].贵州医药,2005,29(1):13-15. 被引量:7
  • 2谢娟,刘方欣,王颖,李少林.^(99)Tc^m-EC-ASODN反义探针的合成和标记[J].核技术,2005,28(6):449-453. 被引量:7
  • 3P Winnard Jr, F Chang, M Rusckowski, et ak Preparation and use of NHS-MAG- for Technetium-^99m labeling of DNA[J]. Nuclear Medicine & Biology, 1997, 24 : 425-432.
  • 4Reddy,-J-A, Low,-P-S. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit-Rev-Ther-Drug-Carrier-Syst, 1998- 15(6): 587-627.
  • 5Ginobbi P,Geiser TA,Ombres D, et al. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligonucleotides on human melanoma (M14) cells. Anticancer Res,1997,17:29-35.
  • 6Orr RB, Kreisler A_R, Kamen BA. Similarity of folate receptor expression in - 38 cells to squamous cell carcinoma differentiation markers. J Natl Cancer Inst,1995,87: 299-303.
  • 7Konecny G, Untch M, Arboleda J, et al. Her-2/neu and Urokinase-type plasminogen activatior and its inhibitor in breast cancer[J]. Clin Cancer Res, 2001,7 (8) : 2448-2457.
  • 8Zhang-Y-M, Rusckowski-M, Liu-N, et al. Cationic liposomes enhance cellular/nuclear localization of 9^9m Tc-antisense oligonucleotides in target tumor cells[J]. Cancer-Biother- Radiopharm,2001,16(5) : 411-419.
  • 9Fereshteh Zareneyrizi, David J Yang, Chang-Sok Oh, et al. Synthesis of [^99m Tc] ethylenedicysteine- colchicine for evaluation of antiangiogenic effect[J]. Anti-Cancer Drugs, 1999,10: 685-692.
  • 10Seyfettin Ilgan, David J Yang, Tetsuya Higuchi, et al. ^99m Tc-Ethylenedicysteine-Folate: A New Tumor Imaging Agent Synthesis,Labeling and Evaluation in Animals[J].1998,13(6):427-435.

共引文献6

同被引文献12

  • 1谢娟,郭坤亮,李少林.叶酸受体介导^(99m)Tc标记c-erbB2癌基因反义寡核苷酸的乳腺癌细胞摄取率[J].贵州医药,2005,29(1):13-15. 被引量:7
  • 2谢娟,李启桢,杨娟,熊世娟.HER-2反义寡脱氧核苷酸对乳腺癌细胞的影响[J].贵州医药,2005,29(11):963-965. 被引量:1
  • 3Fan Z,Chakravarty P, Alferi A,et al. Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cell to radiation[J]. Cancer Gene Ther, 2000, 7 (10) : 1307-1314.
  • 4Harari D, Yaraden Y. Molecular mechanisms underlying erbB-2/HER-2 action in breast cancer[J]. Oncogene, 2000,19 (53) : 6102-6114.
  • 5Van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER-2)[J]. Eur J Cancer, 2001,37(Suppl 1) : 11-17.
  • 6Konecny G, Untch M, Arboleda J, et al. Her-2/neu and Urokinase-type plasminogen activatior and its inhibitor in breast cancer[J]. Clin Cancer Res,2001,7(8):2448- 2457.
  • 7The pharmaceutical journal group. Breast cancer drugs show synergistic effect when given in combination[J]. The Pharmaceutical Journal, 2002,268 (7183 ) : 130.
  • 8Konecoy G, Pegram MD, Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with herceptin against human breast cancer cells with HER- 2/neu overexpression[J].Breast Cancer Res Treat, 1999,57:114.
  • 9Wiles DW, Harris WH, Gillett CE, et ak Effect of c-erbB(2) and estrogn receptor status on survival of woman with primary breast cancer, treated with adjuvant cyclophosphamide/methotrexate/fluoroumcil [J ]. Int J Cancer, 1999,84: 354-359.
  • 10Stal O, Sullivan S, Wingren S, et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer[J]. Eur J Cancer, 1995,31A: 2185- 2190.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部